Masuda Masami, Hasegawa Masato, Nonaka Takashi, Oikawa Takayuki, Yonetani Motokuni, Yamaguchi Yoshiki, Kato Koichi, Hisanaga Shin-Ichi, Goedert Michel
Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan.
FEBS Lett. 2009 Feb 18;583(4):787-91. doi: 10.1016/j.febslet.2009.01.037. Epub 2009 Feb 4.
The conversion of soluble peptides and proteins into amyloid fibrils and/or intermediate oligomers is believed to be the central event in the pathogenesis of most human neurodegenerative diseases. Existing treatments are at best symptomatic. Accordingly, small molecule inhibitors of amyloid fibril formation and their mechanisms are of great interest. Here we report that the conformational changes undergone by alpha -synuclein as it assembles into amyloid fibrils can be detected by epitope-specific antibodies. We show that the conformations of polyphenol-bound alpha-synuclein monomers and dimers differ from those of unbound monomers and resemble amyloid fibrils. This strongly suggests that small molecule inhibitors bind and stabilize intermediates of amyloid fibril formation, consistent with the view that inhibitor-bound molecular species are on-pathway intermediates.
可溶性肽和蛋白质转化为淀粉样纤维和/或中间寡聚体被认为是大多数人类神经退行性疾病发病机制中的核心事件。现有的治疗方法充其量只是缓解症状。因此,淀粉样纤维形成的小分子抑制剂及其作用机制备受关注。在此我们报告,α-突触核蛋白组装成淀粉样纤维时所经历的构象变化可通过表位特异性抗体检测到。我们表明,与多酚结合的α-突触核蛋白单体和二聚体的构象不同于未结合单体的构象,且类似于淀粉样纤维。这有力地表明小分子抑制剂结合并稳定了淀粉样纤维形成的中间体,这与抑制剂结合的分子物种是途径上中间体的观点一致。